Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ADORA3 | P0DMS8 | 9/20 | 0.59 |
| ▸ | ADORA1 | P30542 | 9/20 | 0.59 |
| ▸ | ADORA2A | P29274 | 7/20 | 0.45 |
| ▸ | ADORA2B | P29275 | 5/20 | 0.45 |
| ▸ | HTR2A | P28223 | 1/20 | 0.43 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.43 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.43 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.43 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.43 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.43 |
| ▸ | P2RY1 | P47900 | 1/20 | 0.42 |
| ▸ | CTSL | P07711 | 9/20 | 0.41 |
| ▸ | CTSS | P25774 | 2/20 | 0.40 |
| ▸ | CTSK | P43235 | 1/20 | 0.40 |
| ▸ | CTSB | P07858 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL259363 | 0.91 | ADORA3 (0.48) | ADORA3ADORA1ADORA2AADORA2BCTSL | |
| SCHEMBL258849 | 0.86 | ADORA2A (0.48) | ADORA3ADORA1ADORA2AADORA2B | |
| SCHEMBL15633799 | 0.82 | ADORA3 (0.50) | ADORA3ADORA1ADORA2AADORA2B | |
| SCHEMBL5521464 | 0.81 | ADORA3 (0.50) | ADORA3ADORA1ADORA2AADORA2BP2RY1 | |
| SCHEMBL258946 | 0.81 | ADORA3 (0.52) | ADORA3ADORA1ADORA2AADORA2BP2RY1 | |
| SCHEMBL8306794 | 0.75 | ADORA3 (0.49) | ADORA3ADORA1ADORA2AADORA2B | |
| SCHEMBL6829151 | 0.74 | ADORA2A (0.40) | ADORA3ADORA1ADORA2AADORA2B | |
| SCHEMBL259070 | 0.74 | ADORA3 (0.46) | ADORA3ADORA1ADORA2AADORA2BCTSL | |
| SCHEMBL259555 | 0.74 | ADORA3 (0.47) | ADORA3ADORA1ADORA2AADORA2BCTSL | |
| SCHEMBL119964 | 0.73 | ADORA1 (0.70) | ADORA3ADORA1ADORA2AADORA2BCYP1A2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8133880-B2 | Purine derivatives and methods of use thereof | INOTEK PHARMACEUTICALS CORPORATION (US) | 2012-03-13 | — | — | US | disclosed |
| EP-1802316-B1 | PURINE DERIVATIVES AND METHODS OF USE THEREOF | INOTEK PHARMACEUTICALS CORP (US) | 2011-11-02 | — | — | EP | disclosed |
| US-20110059915-A1 | PURINE DERIVATIVES AND METHODS OF USE THEREOF | INOTEK PHARMACEUTICALS CORPORATION (US) | 2011-03-10 | — | — | US | disclosed |
| US-7863253-B2 | Purine Derivatives and methods of use thereof | INOTEK PHARMACEUTICALS CORPORATION (US) | 2011-01-04 | — | — | US | disclosed |
| EP-1996020-A2 | PURINE COMPOUNDS AND METHODS OF USE THEREOF | Inotek Pharmaceuticals Corporation (US) | 2008-12-03 | — | — | EP | disclosed |
| US-20070238694-A1 | Purine compounds and methods of use thereof | INOTEK PHARMACEUTICALS CORPORATION (US) | 2007-10-11 | — | — | US | disclosed |
| WO-2007111954-A2 | PURINE COMPOUNDS AND METHODS OF USE THEREOF | INOTEK PHAMACEUTICALS CORPORATION (US) | 2007-10-04 | — | — | WO | disclosed |
| EP-1802316-A2 | PURINE DERIVATIVES AND METHODS OF USE THEREOF | Inotek Pharmaceuticals Corporation (US) | 2007-07-04 | — | — | EP | disclosed |
| US-20060128652-A1 | Purine derivatives and methods of use thereof | INOTEK PHARMACEUTICALS CORPORATION | 2006-06-15 | — | — | US | disclosed |
| WO-2006034190-A2 | PURINE DERIVATIVES AND METHODS OF USE THEREOF | INOTEK PHARMACEUTICALS CORPORATION (US) | 2006-03-30 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070238694-A1 | Purine compounds and methods of use thereof | PNP, ADORA2A, P2RY1 | ADORA3 28/4885ADORA1 9/4885ADORA2A 2/4885 |
| US-20110059915-A1 | PURINE DERIVATIVES AND METHODS OF USE THEREOF | PNP, NUDT1, HPRT1 | ADORA3 26/4885ADORA1 22/4885ADORA2A 4/4885 |
| US-20060128652-A1 | Purine derivatives and methods of use thereof | PNP, NUDT1, HPRT1 | ADORA3 26/4885ADORA1 22/4885ADORA2A 4/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.